WorldQuant Millennium Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$31.3M Buy
237,904
+149,658
+170% +$19.9M 0.12% 177
2025
Q4
$12.5M Buy
88,246
+26,226
+42% +$3.8M 0.05% 251
2025
Q3
$8.71M Buy
+62,020
New +$8.4M 0.04% 256
2025
Q1
Sell
-154,852
Closed -$21.1M 481
2024
Q4
$21.1M Buy
154,852
+47,370
+44% +$5.86M 0.14% 177
2024
Q3
$12.4M Sell
107,482
-51,003
-32% -$6.99M 0.09% 215
2024
Q2
$21.8M Buy
158,485
+89,024
+128% +$12.2M 0.2% 142
2024
Q1
$9.58M Buy
69,461
+50,766
+272% +$6.93M 0.12% 198
2023
Q4
$2.46M Sell
18,695
-3,031
-14% -$349K 0.03% 264
2023
Q3
$2.44M Sell
21,726
-97,430
-82% -$10.3M 0.04% 267
2023
Q2
$11.2M Sell
119,156
-149,155
-56% -$14.6M 0.19% 161
2023
Q1
$27.2M Buy
268,311
+17,239
+7% +$1.79M 0.5% 74
2022
Q4
$30M Buy
251,072
+160,466
+177% +$18.8M 0.68% 35
2022
Q3
$9.62M Buy
+90,606
New +$9.19M 0.23% 131
2020
Q3
Sell
-103,004
Closed -$12.6M 352
2020
Q2
$12.6M Sell
103,004
-30,740
-23% -$3.4M 0.29% 116
2020
Q1
$11.6M Buy
133,744
+128,234
+2,327% +$12.5M 0.28% 116
2019
Q4
$592K Buy
+5,510
New +$577K 0.01% 297

Other funds holding NBIX

WorldQuant Millennium Advisors's NBIX Position: Q1 2026 in Review

WorldQuant Millennium Advisors increased its Neurocrine Biosciences (NBIX) stake by 170% in Q1 2026, buying an estimated $19.9M and bringing the position to 237,904 shares worth $31.3M. The position accounts for 0.12% of the portfolio, ranked #177.

WorldQuant Millennium Advisors first reported a position in NBIX in Q4 2019 and has held it in 16 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • WorldQuant Millennium Advisors held 237,904 shares of Neurocrine Biosciences worth $31.3M as of Q1 2026.
  • WorldQuant Millennium Advisors bought 149,658 Neurocrine Biosciences shares in Q1 2026, an estimated $19.9M.
  • Neurocrine Biosciences made up 0.12% of WorldQuant Millennium Advisors's portfolio in Q1 2026, its #177 holding.
  • WorldQuant Millennium Advisors first reported a position in Neurocrine Biosciences in Q4 2019 and has held it in 16 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on WorldQuant Millennium Advisors's 13F filing for Q1 2026, filed 15 May 2026.